You are here: Industry Insights > first-in-class

News List

Monthly News Review of PharmaSources (February) - R&D Caicai/PharmaSources
March 13, 2023
In R&D, Chipscreen chidamide Ⅲ test reaches preset indicators, the company plans to submit an application for the marketing of a new indication.
AstraZeneca, FibroGen give China bragging rights to first-in-class anemia drug approval fiercepharma
December 20, 2018
It is a rare event, if not a singular one in the biopharma world: A first-in-class drug developed by multinational pharma companies was filed first—and now approved first—in China, well before the U.S., EU or Japan.
AstraZeneca, FibroGen give China bragging rights to first-in-class anemia drug approval fiercepharma
December 20, 2018
It is a rare event, if not a singular one in the biopharma world: A first-in-class drug developed by multinational pharma companies was filed first—and now approved first—in China, well before the U.S., EU or Japan.
Ardelyx’s first-in-class NHE3 blocker Tenapanor boasts positive phase III data pharmaceutical-technology
May 27, 2017
On May 12, Ardelyx announced positive top-line results from the T3MPO-1 Phase III study for the use of tenapanor to treat patients with constipation predominant Irritable Bowel Syndrome (IBS-C).
First-in-class innovation a key strategy for harsh pharma market environment europeanpharmaceuticalreview
May 17, 2017
Fewer than two in 10 medicines exceed the average pharmaceutical R&D cost required to bring a drug to market when the risks of failure to reach market approval are factored in, according to business intelligence provider GBI Research.